ABSTRACT

There is growing concern regarding the increased resistance rates of numerous pathogens and the limited availability of new antibiotics against these pathogens. In this context, fosfomycin is of considerable interest due to its activity against a wide spectrum of these microorganisms. We will review the encouraging data on this issue regarding the use of fosfomycin in treating Gram-negative bacterial infections. We will also cover fosfomycin's role against 2 of the main causal agents of bacteremia and endocarditis worldwide (nosocomial and community-acquired): enterococci, whose growing resistance to glycopeptides and aminoglycosides represents a serious threat, and methicillin-resistant Staphylococcus aureus, whose infection, despite efforts, continues to be associated with high morbidity and mortality and a high risk of complications. Thanks also to its considerable synergistic capacity with various antibiotics, fosfomycin is a tool for extending the therapeutic arsenal against these types of infections.

Keywords: Fosfomycin, Bacteremia, Infectious endocarditis, Methicillin-resistant Staphylococcus aureus, Gram-negative.

BACKGROUND

There has been a worrying increase in the rates of antibiotic resistance among Gram-positive and Gram-negative pathogens, representing an increase in mortality and hospital stays, thereby impelling the search for alternative treatment strategies. Given the limited availability of new antimicrobials, the reassessment of earlier compounds appears to be an interesting option. Fosfomycin has raised considerable interest, given that, despite being an older antibiotic, it remains active against a wide spectrum of problematic pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), glycopeptide-resistant enterococci and multidrug-resistant enterobacteria. Fosfomycin's single mechanism of action, along with its broad spectrum and synergistic potential with other antibiotics, makes it a promising candidate for treating patients with complex systemic infections.

FOSFOMYCIN

Discovered in Spain in 1969 [1], fosfomycin is a bactericidal drug that inhibits cell wall synthesis [2], preventing the formation of the N-acetylmuramic acid of the bacterial wall peptidoglycan. This inhibitory action occurs in one step prior to the action of beta-lactams and glycopeptides. Fosfomycin is a water-soluble agent with a low molecular weight (138 g/mol) and very low protein binding, which provides it with high tissue dissemination. Fosfomycin also penetrates and disseminates adequately in biofilms, not only acting on microorganisms but also changing their structure [3]. Fosfomycin is eliminated almost exclusively through glomerular filtration. The pharmacokinetic-pharmacodynamic effectiveness parameter to consider for achieving the therapeutic objective is the area under the curve/minimum inhibitory concentration; fosfomycin also presents a postantibiotic effect.

New evidence on the use of fosfomycin for bacteremia and infectious endocarditis

Servicio de Anestesia, Unidad de Cuidados Críticos Quirúrgicos, Hospital Universitario La Paz, Madrid

Javier Veganzones
Ana Montero
Emilio Maseda

Correspondence:
Emilio Maseda
Servicio de Anestesia, Cuidados Críticos Quirúrgicos, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid
Tfno.: 917277273
E-mail: emilio.maseda@gmail.com
als [8]. Fosfomycin’s single mechanism of action makes cross-resistance uncommon and enables synergy with other antimicrobials [9], as demonstrated by numerous studies in the literature that will be discussed later. In general, fosfomycin is considered a safe drug. Nevertheless, there have been reported cases of heart failure secondary to sodium overload after the administration of fosfomycin’s intravenous formulation [10].

**GRAM-NEGATIVE BACTEREMIA**

Most data that support the use of fosfomycin in infections caused by multidrug-resistant Gram-negative microorganisms originate from observational studies that involved a very limited number of patients, in which fosfomycin was generally employed as part of a regimen in combination with other agents. All this, coupled with the lack of an additional comparator group, limit the conclusions that can be extracted from the available data.

Bacteremic infections caused by multidrug-resistant Gram-negative microorganisms have a poor prognosis. The early diagnosis and start of optimal antimicrobial therapy are essential for improving results. A cohort study conducted in a Spanish hospital from 2010 to 2012 that included 40 patients with bacteremia by OXA-48 carbapenemase-producing *Enterobacteriaceae* observed a mortality rate of 65%. The patients were mostly elderly with significant comorbidities (57.5% with underlying malignancy) and had been exposed to antibiotics and invasive procedures during their hospitalization. The most common source of bacteremia was urinary. Amikacin, colistin and fosfomycin were the antibiotics that most often maintained their effectiveness against OXA-48 isolates, but none were uniformly active in isolation. The patients were treated mostly with combinations of antibiotics active against the involved pathogen, employing monotherapy only in highly selected cases (patients with less severe infection and controlled foci). Of the 5 patients who were treated with intravenous fosfomycin (4 underwent combined therapy with colistin, and 1 underwent combined therapy with tigecycline), death due to the infection was reported in 2 [11].

**Role of fosfomycin.** Preliminary data on the use of fosfomycin in combination with other agents for treating bacteremic infections by multidrug-resistant Gram-negative microorganisms are encouraging. There is an ongoing clinical trial whose main objective is to demonstrate the clinical noninferiority of fosfomycin compared with meropenem in the targeted treatment of bacteremic infections caused by ESBL-producing *Escherichia coli*. The multicenter study included patients with bacteremia secondary to urinary tract infection caused by ESBL-producing *E. coli*. Using a randomized assignment system, the patients were assigned to one of the following treatment arms: intravenous fosfomycin disodium 4 g/6 h or intravenous meropenem 1 g/8 h. The secondary endpoints included hospital mortality, mortality at 30 days, recurrence rate, length of stay, safety and the development of fosfomycin resistance [12].

**BACTEREMIA/INFECTIOUS ENDOCARDITIS DUE TO *S. AUREUS***

Staphylococcal bacteremia is a severe entity with high morbidity and mortality and a high risk of complications such as hematogenous dissemination and endocarditis. Staphylococcal bacteremia is one of the main causes of bacteremia worldwide (both nosocomial and community-acquired), with an incidence rate that ranges from 10 to 30 cases per 100,000 person-years. Despite efforts to manage this infection, staphylococcal bacteremia continues to present high mortality, as demonstrated by a recent multinational observational study that analyzed databases from several European institutions. The study showed a mortality rate of 29% at 90 days, although this rate varied with patient age, patient characteristics and focus of infection [13]. In addition to high mortality, these infections are associated with high morbidity and healthcare costs due to prolonged hospitalizations and antibiotic therapies. The factors that influence the prognosis of staphylococcal bacteremia can be divided into 2 categories:

First, we have unmodifiable factors that include those associated with the host (e.g., age, comorbidities), with the pathogen (MRSA) and with the focus of infection, where infectious endocarditis is especially prominent (with its currently mortality rate of 16-25%) and where *S. aureus* has become the leading cause of staphylococcal bacteremia in the developed world [14]. It is also worth noting the global increase in the prevalence of MRSA infections and the associated epidemiological changes, which mainly include an increase in age, the presence of more comorbidities and nosocomial acquisition. Additionally, MRSA infection has been identified as an independent risk factor for mortality, as observed in a large, observational, multicenter Spanish study that included more than 600 episodes of MRSA bacteremia, with a mortality rate >30% regardless of the type of antibiotic therapy administered [15].

Secondly and in terms of modifiable factors, we have those related to the management, early diagnosis, control of foci and appropriate antibiotic therapy. Circumstances, such as the location of the infection, a high bacterial load and the presence of foreign material, as occurs in valve vegetations and abscesses, are especially important because they can hinder management and therapeutic efficacy.

**Role of fosfomycin.** According to the recommendations of the latest guidelines [16, 17], vancomycin is currently considered the first treatment option for MRSA bacteremia and endocarditis, along with daptomycin (both in monotherapy). However, therapeutic failures have been reported in the literature, as well as the emergence of resistances both to vancomycin and to daptomycin that can reach 15% [18, 19]. Specifically, MRSA strains with MICs for vancomycin ≥2 mg/L have increased from 5.6% in 2004 to 11.1% in 2009 and are associated with poorer results [20, 21].

In this context, fosfomycin can play an important role in broadening the therapeutic arsenal against this type.
of infection because it presents very good activity versus methicillin-susceptible *Staphylococcus aureus* (MSSA) and MRSA, with susceptibility rates >95%.

**Combined therapy.** Several studies have also analyzed the synergistic capacity of fosfomycin with various antibiotics [10]. In the specific case of MRSA, studies have observed that MRSA reduces PBP2A expression in the presence of fosfomycin, thereby increasing the susceptibility to beta-lactams. Experimental models of endocarditis (*in vitro and in vivo*) have therefore evaluated the effectiveness of fosfomycin combined with various beta-lactams against MRSA and strains intermediate to glycopeptides. Of these combinations, the one with imipenem is the most active [22]. This multicenter study assessed the clinical efficacy and safety of fosfomycin combined with imipenem as rescue therapy for 16 patients with MRSA endocarditis or complicated bacteremia. The blood cultures became negative 72 h after the first doses in all cases, and the cure rate was 69%, with only 1 death attributable to MRSA. The combination was safe in 94% of the cases, although a patient with hepatic cirrhosis died of multiorgan failure secondary to sodium overload [23]. More recently, the same team conducted a randomized clinical trial to assess the safety and efficacy of imipenem combined with fosfomycin in treating MRSA bacteremia and endocarditis, compared with vancomycin alone. Although the study had defects in its recruitment, and the final sample did not allow for a robust analysis, the study provided a proof-of-concept that warrants future investigations [24].

Although the experience is limited, synergistic *in vitro* activity has been observed between fosfomycin and daptomycin, and some cases have been treated successfully [25, 26]. A clinical trial currently underway [27] randomized patients with MRSA bacteremia to treatment with daptomycin in monotherapy or in combination with fosfomycin. There are also studies on the synergistic activity with linezolid, with good *in vitro* results [28].

In 2013, the guidelines of the Spanish Society of Chemotherapy on the treatment of staphylococcal infection [29] placed fosfomycin as a therapeutic option to consider in MRSA endocarditis on native valves. More recently, other guidelines [18, 30] have included the use of fosfomycin as an alternative in combination with cloxacillin, daptomycin or imipenem for treating infections complicated by MSSA or MRSA.

Bacteremia by *S. aureus*, including infectious endocarditis, entails high mortality, and up to 50% of patients experience failure with the initial therapy with vancomycin and require rescue therapy. New strategies (including the use of fosfomycin) are therefore needed to effectively treat these patients and could require combined therapies such as rescue therapy.

**BACTEREMIA/INFECTIOUS ENDOCARDITIS DUE TO ENTEROCOCCUS SPP.**

*Enterococcus* spp. has become the third leading cause of nosocomial bacteremia, which is significantly associated with the risk of developing infectious endocarditis [15]. Infectious enterococcal endocarditis is mainly caused by *Enterococcus faecalis* (90% of cases) and, more rarely, by *E. faecium* (5%). The medical treatment of enterococcal endocarditis is a challenge for 2 reasons: 1) Enterococci are highly resistant to antibiotic-induced death, and suppressing enterococci requires extended administration (up to 6 weeks) of synergistic bactericidal combinations of 2 cell-wall inhibitors (ampicillin plus ceftriaxone) or a cell-wall inhibitor with aminoglycosides, and 2) enterococci are resistant to numerous antibiotics such as penicillins and cephalosporins and have a growing resistance to glycopeptides and aminoglycosides [31]. The combination of high-dose penicillin or ampicillin and an aminoglycoside (streptomycin or gentamicin) typically cures enterococcal endocarditis; however, resistance to aminoglycosides is a significant problem and threat. New therapeutic options such as synergistic combinations should be assessed [10]. Fosfomycin could therefore have a useful role, and its combination with ceftriaxone could be considered a therapeutic option in the antibiotic treatment of endocarditis by *E. faecalis* [32].

**REFERENCES**

1. Hendlin D, Staple EO, Jackson M, Wallick H, Miller AK, Wolf FJ, et al. Phosphonomycin, a new antibiotic produced by strains of streptomycetes. Science. 1969; 166:122–123. doi:10.1126/science.166.3901.122.

2. Skarzynski T, Mistry A, Wonacott A, Hutchinson SE, Kelly VA, Duncan K. Estructura de UDP-N-acetilglucosamina enolpiruvil transfe- rasa, una enzima esencial para la síntesis de peptidoglicano bacteriano, complejado con sustrato UDP-N-acetilglucosamina y la droga fosfomicina. Estructura 4 1996;1465-1474. doi:10.1016 / S0969-2126 (96) 00153-0.

3. Anderson GG, Kenney TF, Macleod DL, Henig NR, O'Toole GA. Eradication of *Pseudomonas aeruginosa* biofilms on cultured airway cells by a fosfomycin/trimethoprim antibiotic combination. Pathog Dis 2013; 67:39-45. doi:10.1111/2049-632X.12015.

4. Falagas ME, Roussos N, Gkegkes ID, Rafailidis PI, Karageorgopoulos DE. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin Invest Drugs 2009;18:921–944. doi:10.1517/135437809002967624.

5. Descourrouez JL, Jorgenson MR, Wergin JE, Rose WE. Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant *Enterococcus faecium* from renal transplant patients with infected urinary stents. Antimicrob Agents Chemother 2013;57:1518–1520. doi:10.1128/AAC.02099-12.

6. Falagas ME, Katoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010; 10:43–50. doi:10.1016/S1473-3099(09)70325-1.

7. Falagas ME, Katoris AC, Karageorgopoulos DE, Rafailidis PI. Fos- fomycin for the treatment of infections caused by multidrug-resistant...
sistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents 2009; 34:111–120. doi:10.1016/j.ijantimicag.2009.03.009.
8. Krause R, Patruta S, Daxbock F, Fladerer P, Wenisch C. The effect of fosfomycin on neutrophil function. J Antimicrob Chemother 2001;47:141–146. doi:10.1093/jac/47.2.141.
9. Kastoris AC, Rafaiilidis PI, Vouloumanou EK, Gekgtes ID, Falagas ME. Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria. Eur J Clin Pharmacol 2010;66:359–368. doi:10.1007/s00228-010-0794-5.
10. Florent A, Chichmanian RM, Cua E, Pulcini C. Adverse events associated with intravenous fosfomycin. Int J Antimicrob Agents 2011;37:82–83. doi:10.1016/j.ijantimicag.2010.09.002.
11. Navarro-San Francisco, Mora-Rillo M, Romero-Gómez MP et al. Bacteremia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge. Clin Microbiol Infect. 2013 Feb;19(2):E72-9. doi: 10.1111/1469-0691.12091.
12. Rosso-Fernández, Sojo-Dorado, Barriga et al. Fosfomycin versus meropenem in bacteremic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial. BMJ Open. 2015 Mar 31;5(3):e007363. doi: 10.1136/bmjopen-2014-007363.
13. Kaasch AJ, Barlow G, Edgeworth JD et al. Staphylococcus aureus infection: a pooled analysis of five national prospective hospital-based cohort studies. J Infect. 2014; 68(3): 242–251. doi:10.1016/j.jinf.2013.10.015.
14. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Tleyjeh IM, Rybak MJ et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015;132:1435–1486. doi: 10.1161/CIR.0000000000000296.
15. Gasch O et al. Predictive factors for mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infection: impact on outcome of host, microorganism and therapy. Clin Microbiol Infect 2013;19:1049–57. doi: 10.1111/1469-0691.12108
16. Liu C Bayor A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18e55. doi: 10.1093/cid/ciq146.
17. Habib G, Lancelotti P, Antunes MJ. ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC): endorsed by European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36:3075–3128. doi: 10.1093/eurheartj/ehv319
18. Gasch O, Cameoz M, Dominguez MA, Padilla B, Pintado V, Almirante B, et al. Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteremia treated with daptomycin. J Antimicrob Chemother 2014;69:568–571. DOI: 10.1093/jac/dkt1396.
19. Fowler VG Jr, Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. New Engl J Med 2006; 355: 363. doi: 10.1056/NEJMoa053783.
20. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008; 46(2):193–200. Doi: 10.1086/524667.
21. van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gospell IB. Predictors of mortality in Staphylococcus aureus bacteremia. Clin Microbiol Rev. 2012; 25(2):362–86. doi:10.1128/CMB.00222-11.
22. del Rio A, García-de-la-María C, Entenza JM, Gasch O, Armery Y, Soy D, et al. Fosfomycin plus β-lactams as synergistic bactericidal combinations for experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2015; 60:478–486. doi:10.1128/AAC.02139-15.
23. del Rio A, Gasch O, Moreno A, Peña C, Cuquet J, Soy D, et al. Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial. Clin Infect Dis 2014; 59:1105–1112. Doi: 10.1093/cid/ciu580.
24. Pericás JM, Moreno A, Almela M, García-de-la-María C, Marco F, Muñoz P et al. Efficacy and Safety of Fosfomycin-Plus Imipenem vs. Vancomycin for Complicated Bacteremia and Endocarditis Due to Methicillin-Resistant Staphylococcus aureus: A Randomized Clinical Trial. Clin Microbiol Infect. 2018;24(6):673-676. doi: 10.1016/j.cmi.2018.01.010.
25. Miró JM, Entenza JM, Del Rio A et al. High-Dose daptomycin plus fosfomycin is safe and effective in treating MSSA and MRSA endocarditis. Antimicrob Agents Chemother 2012; 56: 4511–5. doi:10.1128/AAC.06449-11.
26. Chen et al: High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: Case report. BMC Infectious Diseases 2011; 11:152. doi:10.1186/1471-2334-11-152.
27. Shaw E, Miró JM, Puig-Asensio M et al. Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial. BMJ Open 2015;5:e006723. doi:10.1136/bmjopen-2014-006723.
28. Yu Xu-hong et al. In vitro activity of fosfomycin in combination with linezolid against clinical isolates of methicillin-resistant Staphylococcus aureus. J Antibiot (Tokyo). 2014,67(5):369-71. doi:10.1038/aj.2014.5.
29. Mensa J, Soriano A, Llinares P, Barberán J, Montejo M, Salvavert M et al. Guidelines for antimicrobial treatment of the infection by Staphylococcus aureus. Rev Esp Quimioter. 2013;26 Suppl 1:1-84. PMID: 23824510.
30. Gudiol F, Aguado JM, Almirante B et al. Executive summary of the diagnosis and treatment of bacteremia and endocarditis due to Staphylococcus aureus. A clinical guideline from the Spanish Society of Infectious Diseases and Clinical Microbiology.
Society of Clinical Microbiology and Infectious Diseases (SEIMC). Enferm Infec Microbiol Clin 2015; 33(9): 626-32. Doi: 10.1016/j.eimc.2015.03.014.

31. Habib G et al. Guía ESC 2015 sobre el tratamiento de la endocarditis infecciosa. Rev Esp Cardiol. 2016;69(1):69.e1-e49. Doi:10.1016/j.recesp.2015.11.015.

32. Farina C et al. In vitro Activity Effects of Twelve Antibiotics Alone and in Association against Twenty-Seven Enterococcus faecalis Strains Isolated from Italian Patients with Infective Endocarditis: High in vitro Synergistic Effect of the Association Ceftriaxone-Fosfomycin. Chemotherapy 2011;57:426–433. doi: 10.1159/000330458.